Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 71Lung Neoplasms 32Triple Negative Breast Neoplasms 23Breast Neoplasms 19Small Cell Lung Carcinoma 15Ovarian Neoplasms 15Squamous Cell Carcinoma of Head and Neck 13Endometrial Neoplasms 13Neoplasms 12Parkinson Disease 4, Autosomal Dominant Lewy Body 10Fallopian Tube Neoplasms 10Neoplasm Metastasis 9Colorectal Neoplasms 6Urinary Bladder Neoplasms 5Carcinoma 5Adenocarcinoma of Lung 5Esophageal Neoplasms 4Uterine Cervical Neoplasms 3Pathologic Complete Response 3Pancreatic Neoplasms 3Oropharyngeal Neoplasms 3Mesothelioma 3Melanoma 3Lung Diseases 3Head and Neck Neoplasms 3Esophageal Squamous Cell Carcinoma 3Central Nervous System Neoplasms 3Uterine Neoplasms 2Thoracic Neoplasms 2Sarcoma 2

Interventions

pembrolizumab 2tremelimumab 1poly ICLC 1lenvatinib 1durvalumab 1balstilimab 1Peptides 1Pemetrexed 1Carboplatin 1Blood Specimen Collection 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Diabetes Mellitus, Insulin-Dependent, 12 × Carboplatin × 30 days × Clear all
NCT03530397 2026-05-19

A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors

MedImmune LLC

Phase 1 Active not recruiting
400 enrolled

Diabetes Mellitus, Insulin-Dependent, 12, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡